Solventum Co. (NYSE:SOLV) Shares Sold by Huntington National Bank

Huntington National Bank cut its position in Solventum Co. (NYSE:SOLV) by 26.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,304 shares of the company’s stock after selling 3,282 shares during the quarter. Huntington National Bank’s holdings in Solventum were worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the company. Davis Selected Advisers acquired a new stake in Solventum during the 2nd quarter valued at approximately $273,070,000. Nuance Investments LLC acquired a new stake in shares of Solventum during the second quarter worth approximately $115,829,000. Newport Trust Company LLC bought a new stake in shares of Solventum in the second quarter worth $98,976,000. Baupost Group LLC MA acquired a new stake in Solventum in the second quarter valued at $96,242,000. Finally, Magnetar Financial LLC boosted its stake in Solventum by 2,880.8% during the 2nd quarter. Magnetar Financial LLC now owns 1,490,410 shares of the company’s stock valued at $78,813,000 after acquiring an additional 1,440,410 shares during the last quarter.

Solventum Price Performance

SOLV stock opened at $67.48 on Friday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $96.05. The stock’s fifty day moving average is $70.54 and its two-hundred day moving average is $62.22.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Piper Sandler increased their price target on shares of Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Stifel Nicolaus assumed coverage on Solventum in a report on Tuesday, October 8th. They set a “buy” rating and a $82.00 target price on the stock. Wolfe Research began coverage on Solventum in a report on Thursday, September 26th. They issued a “peer perform” rating for the company. Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a research note on Monday, November 11th. Finally, BTIG Research started coverage on shares of Solventum in a research note on Thursday, September 5th. They set a “neutral” rating for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $68.00.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.